Alves Sandra Isabelle Barros 4

What Happened
Sandra Alves, SVP, Finance and CAO of Repare Therapeutics (RPTX), recorded dispositions on 2026-01-28 totaling 82,122 shares/units (31,622 shares + 26,000 + 24,500 derivatives). These dispositions were made "to the issuer" and were part of the Arrangement Agreement under which Xeno Acquisition Corp. acquired Repare. Under that agreement common shares/RSUs were cancelled for $2.20 in cash per share plus one non-transferable contingent value right (CVR) per share; options/other derivatives were cancelled for $2.20 less the applicable exercise price plus one CVR per underlying share. The Form 4 lines show N/A or $0 for some items due to how the cancellation/derivative payoffs are reported.

Key Details

• Transaction date: 2026-01-28 (all listed dispositions).
• Reported amounts on Form 4: 31,622 shares (disposed, reported N/A), 26,000 derivative units (reported $0), 24,500 derivative units (reported $0). Aggregate = 82,122.
• Consideration per footnotes: $2.20 cash per share plus one CVR per share for cancelled common/RSU shares (F1, F2); cancelled options received $2.20 less exercise price plus one CVR per share (F3).
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Filing timeliness: Report filed 2026-01-28 for transactions dated 2026-01-28 (no late filing indicated).

Context
These dispositions were corporate-transaction related (share/option cancellations under an acquisition), not open-market personal sales. Such filings reflect deal consideration rather than an insider expressing a buy/sell opinion. For the derivative cancellations, the cash paid to option holders depends on each option’s exercise price (per F3). The CVR is non-transferable and may have contingent future value separate from the $2.20 cash.